oncodaily - The OLIGOMA trial presented at ESTRO 2026 brings new attention to one of the most debated questions in metastatic breast cancer: can treating limited metastatic sites with stereotactic body radiotherapy […]
AI Summary: A randomized trial shows stereotactic body radiotherapy (SBRT) targeting limited metastatic breast lesions prolongs progression‑free survival, offering longer disease control for selected patients with oligometastatic disease. Toxicity was manageable, suggesting SBRT could become a pragmatic, tissue‑sparing option to delay systemic therapy escalation.
High‑dose targeted radiation shows promise for huge bile duct tumors / 1 month
Two high‑dose radiotherapy sessions safely treat localized prostate cancer / 11 days
ESMO issues new metastatic colorectal cancer clinical guideline / 6 wks
Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 46 hrs
Common asthma drug may overcome immunotherapy resistance in cancers / 11 days
Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 13 days
Zoldonrasib shows durable responses in KRAS G12D lung cancer / 5 wks
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.